• 

  Covishield makers Serum Institute of India responds to heart attack concerns

  Health | July 03, 2025 15:06 IST

  Recent studies conducted by the ICMR and the NCDC have found no direct link between COVID-19 vaccination and reports of unexpected fatalities in the country. The SII took to X to share the studies and responded to heart attack concerns.

• 

  Serum Institute 'hopeful' of producing Mpox vaccine, says CEO Adar Poonawalla

  India | August 21, 2024 8:46 IST

  The Serum Institute of India is working on a vaccine for Monkeypox, with CEO Adar Poonawalla expressing optimism about its development within a year. The initiative follows the World Health Organization's declaration of Monkeypox as a global health emergency.

• 

  India's Serum Institute and Oxford University roll out first Malaria vaccine in Africa's Ivory Coast

  Health | July 16, 2024 16:10 IST

  India's Serum Institute and Oxford University have launched the first malaria vaccine in Ivory Coast, Africa, marking a significant milestone in combating the deadly disease. This collaborative effort aims to save millions of lives in malaria-endemic regions.

• 

  Legal victory for Serum Institute of India in defamation case; anti-Covishield posts to be deleted

  India | June 05, 2023 19:38 IST

  Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory said Bombay High Court.

• 

  Covid vaccine Covovax to get approval as booster in 10-15 days, says Adar Poonawalla

  India | January 09, 2023 7:45 IST

  Speaking to reporters on the sidelines of an event at Bharti Vidyapeeth University, Poonawalla, when asked about states and districts not getting Covishield vaccines, said there are ample stocks with the Union government for supply.

• 

  Covid surge: SII to provide 2crore doses of Covishield vaccine to Centre for free

  India | December 28, 2022 19:16 IST

  Covid surge: SII has so far provided more than 170 crore doses of Covishield to the government for the national immunisation programme.

• 

  Serum Institute seeks drug regulator's approval for market authorisation of Covovax as booster dose

  India | December 25, 2022 13:54 IST

  Covid-19: Earlier on October 17, Prakash Kumar Singh, director of government and regulatory affairs at SII, submitted a market authorization application to the Drug Controller General of India (DCGI) for the heterologous booster dose of Covovax.

• 

  SII stopped Covishield production last year; says Poonawalla; claims 100 mn doses expired

  India | October 21, 2022 7:30 IST

  SII Chief Executive Officer Adar Poonawalla said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic.

• 

  Fraudsters send fake WhatsApp messages in CEO Adar Poonawalla's name, dupe SII of over Rs 1 crore

  India | September 11, 2022 7:38 IST

  Pune news: The fraudsters duped the SII in the name of the institute's CEO Adar Poonawalla. The incident came to light only after a hefty amount of Rs 1.1 crore was transferred by one of the directors, Satish Deshpande.

• 

  Serum Institute's Covovax gets DCGI's nod for emergency use in children aged 7-11 years

  India | December 17, 2022 13:24 IST

  The DCGI's nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years.

• 

  Best investment you'll ever make: Poonawalla woos Musk to invest in making Tesla cars in India

  Business | May 08, 2022 18:24 IST

  Elon Musk, who has made a successful USD 44 billion acquisition bid for Twitter, had in the past asked India to reduce import duties to sell Tesla electric cars but the government has insisted on local manufacturing.

Advertisement
• 

  SII's Covid vaccine Covovax now available for children in India: Adar Poonawalla

  India | May 03, 2022 17:13 IST

  Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, requesting for Covovax's inclusion in the immunisation drive for children aged 12 to 17 years.

• 

  SEC seeks more data from Serum Institute over COVID vaccine 'Covovax' for 7-12 age group: Sources

  India | April 30, 2022 7:40 IST

  Covovax has already been recommended by the Drugs Controller General of India for children above 12 years of age, but its administration has not been allowed yet.

• 

  COVID 19: Govt panel recommends permission for phase-3 trial of Covovax as booster dose in adults

  India | March 06, 2022 16:48 IST

  In February, Director, Government and Regulatory Affairs at Serum Institute of India, Prakash Kumar Singh had sought from DCGI nod to conduct a phase-3, observer-blind, randomized, controlled study to evaluate the safety and immunogenicity of Covovax as a booster dose in adults

• 

  Covishield could soon be available at medical stores as SII seeks full market authorisation nod

  India | December 31, 2021 14:12 IST

  Covishield has been one of the main Covid-19 vaccines used in India for inoculation. Around 90% population have got Covishield.

• 

  Vaccine for children aged 3 years and above to be launched in 6 months: Serum Institute

  India | December 14, 2021 17:23 IST

  Speaking about the Omicron variant, Poonawalla said, "On the back of enough data, it is safe to say that booster vaccine doses are a proven strategy to get antibodies up to a great extent".

• 

  Covovax not approved in country of origin yet, notes govt panel as it seeks data from SII

  India | November 28, 2021 12:27 IST

  The DCGI office had granted SII permission to manufacture and stock Covovax on May 17. Based on the DCGI's approval, till now, the Pune-based firm has manufactured and stockpiled vaccine doses.

• 

  Serum Institute resumes exports of Covishield vaccine

  India | November 26, 2021 18:23 IST

  The vaccine maker has cumulatively produced 1.25 billion doses of COVID-19 vaccines so far, a company statement said.

• 

  Serum Institute seeks regular marketing authorisation from DCGI for Covishield

  India | October 25, 2021 21:51 IST

  If the DCGI grants regular marketing authorisation, Covishield will be the second vaccine in the world to receive such approval. Pfizer-BioNTech's COVID-19 vaccine has received full US FDA approval for use in individuals 16 years of age and older.

• 

  PM Modi meets Indian COVID-19 vaccine manufacturers after Billion doses feat

  India | October 23, 2021 20:17 IST

  Representatives from seven vaccine makers -- Serum Institute of India, Bharat Biotech, Dr Reddy's Laboratories, Zydus Cadila, Biological E, Gennova Biopharma and Panacea Biotech -- participated in the meeting.